(lp0
S"Aviragen Therapeutics Inc : What's Next? Insider Financial - Feb 16, 2017 Aviragen Therapeutics Inc  is not having a good week. The company just put out data from a phase 2 study of its lead development asset, and has taken a close to 40% hit on the news.Aviragen Therapeutics Inc  Downgraded by HC Wainwright - Sports Perspectives"
p1
aS'Aviragen Therapeutics slammed again by its second trial failure in days, this ... Endpoints News - Feb 13, 2017 In back-to-back setbacks, Aviragen Therapeutics $AVIR says that its lead drug vapendavir flunked a Phase IIb in moderate to severe asthmatics with a rhinovirus infection.'
p2
aS'Aviragen Therapeutics Inc. MarketWatch - May 4, 2016 Check out the returns on our 8 Lazy Portfolios that are made up of low-cost buy-and-hold index funds.  How to create your own Lazy Portfolio.'
p3
aS"Aviragen Therapeutics'  CEO Joseph Patti on Q2 2017 Results - Earnings ... Seeking Alpha - Feb 3, 2017 Good day, ladies and gentlemen, and welcome to the Aviragen Therapeutics, Inc. Second Quarter 2017 Financial Results Conference Call.Aviragen Hits 52-Week Low on Drug Failure  - Investopedia"
p4
aS'Biota Pharmaceuticals Is Now Aviragen Therapeutics Seeking Alpha - Apr 27, 2016 Subsequent to our last update on Aviragen Therapeutics, the company has been busy attending and presenting at industry conferences.'
p5
aS"Aviragen Therapeutics'  CEO Dr. Joseph Patti on Q4 2016 Results ... Seeking Alpha - Sep 14, 2016 I would like to welcome you to the Aviragen Therapeutics conference call and webcast to review the Company's fourth quarter and fiscal yearend 2016 earnings results to provide an update on recent pipeline and corporate developments."
p6
aS"Biota Pharma  Becomes Aviragen Therapeutics; Will Trade Under 'AVIR' StreetInsider.com - Apr 12, 2016 Biota Pharmaceuticals, Inc.  announced that the Company has changed its name to Aviragen Therapeutics, Inc., , a pharmaceutical company focused on the development of the next generation of direct-acting&nbsp;..."
p7
aS'Aviragen Therapeutics Receives A New Buy Rating, $5 Target Benzinga - Jul 13, 2016 Aviragen Therapeutics is studying vapendavir 264 mg and 528 mg BID in SPIRITUS, which raises the likelihood of positive results.'
p8
aS"Aviragen Therapeutics  : 2016 Financial Results; Expecting ... Zacks Small Cap Research  - Sep 15, 2016 Based on Aviragen's current operating plans, including Phase 3 trials for vapendavir in 2H 2017, we expect the firm to have significant operating burn."
p9
aS'Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the ... GlobeNewswire  - May 26, 2016 ATLANTA, May 26, 2016  -- Aviragen Therapeutics, Inc.  , a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily&nbsp;...'
p10
a.